This booklet serves as an introduction to cereblon E3 ligase modulatory drugs (CELMoDs), a new class of medications currently being studied in clinical trials for the treatment of myeloma. Although CELMoDs are building on the well-established platform of immunomodulatory agents, CELMoDs are designed to attack myeloma in a novel way. CELMoDs not only kill myeloma cells directly but also by engaging other immune cells. In addition, CELMoDs are able to be used even in myeloma patients who have relapsed after treatment with immunomodulatory agents. Two promising CELMoDs in clinical trials are iberdomide and mezigdomide, and both drugs are taken orally (by mouth).
